Table 3.

Multivariate analysis with Cox Regression model on hormone‐receptor positive patients for PFS and OS

	PFS		OS
Variables	HR (95%CI)	P	HR (95%CI)	P
ECOG PS (1/2 vs. 0)	1.39 (1.0–1.94)	0.05	—	ns
Number of disease site (>1 vs. 1)	1.44 (1.01–2.05)	0.04	—	ns
Bevacizumab maintenance (no vs. yes)	1.52 (1.08–2.14)	0.02	—	ns
Maintenance endocrine therapy (no vs. yes)	2.45 (1.71–3.51)	< 0.0001	4.69 (2.84–7.74)	< 0.0001
Treatment response (no vs. yes)	—	—	1.79 (1.08–2.97)	0.03

PFS, progression‐free survival; OS, overall survival; ECOS PS, eastern cooperative oncology group performance status; HR, hazard ratio.